Protalix BioTherapeutics (PLX) News Today $1.76 +0.02 (+1.15%) (As of 12/20/2024 04:33 PM ET) Add Compare Share Share Headlines Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Analyzing BioCardia (NASDAQ:BCDA) & Protalix BioTherapeutics (NYSE:PLX)December 18 at 2:09 AM | americanbankingnews.comChiesi Global Rare Diseases and Protalix BioTherapeutics Announce Validation of Variation Submission by European Medicines Agency for pegunigalsidase alfaDecember 9, 2024 | prnewswire.comPLX: Self-Sustaining Rise to Lead in Renal Rare DiseaseNovember 15, 2024 | finance.yahoo.comProtalix BioTherapeutics, Inc. (AMEX:PLX) Q3 2024 Earnings Call TranscriptNovember 15, 2024 | insidermonkey.comProtalix BioTherapeutics Inc (PLX) Q3 2024 Earnings Call Highlights: Revenue Surge and ...November 15, 2024 | finance.yahoo.comProtalix BioTherapeutics, Inc. (PLX) Q3 2024 Earnings Call TranscriptNovember 14, 2024 | seekingalpha.comProtalix BioTherapeutics, Inc.: Protalix BioTherapeutics Reports Third Quarter 2024 Financial and Business ResultsNovember 14, 2024 | finanznachrichten.deEarnings Outlook For Protalix BioTherapeuticsNovember 13, 2024 | benzinga.comProtalix BioTherapeutics to Present Phase I PRX-115 Data in Late-Breaking Poster at ACR Convergence 2024October 25, 2024 | finance.yahoo.comOTC Markets Hosts Virtual Investor Presentation with Dror Bashan, President & CEO of Protalix Biotherapeutics, and John Vandermosten, Senior Analyst at Zacks SCROctober 24, 2024 | msn.comProtalix BioTherapeutics to Present at the Life Sciences Investor Forum September 19, 2024September 16, 2024 | globenewswire.comProtalix BioTherapeutics to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 4, 2024 | tmcnet.comProtalix BioTherapeutics Announces Repayment of Outstanding Senior Secured Convertible Promissory NotesSeptember 3, 2024 | prnewswire.comIs Protalix BioTherapeutics, Inc. (PLX) The Best Rated Penny Stock To Buy According to Analysts?August 30, 2024 | msn.comProtalix BioTherapeutics Inc.August 28, 2024 | money.usnews.comProtalix BioTherapeutics, Inc. to Post FY2024 Earnings of $0.06 Per Share, Zacks Small Cap Forecasts (NYSE:PLX)Protalix BioTherapeutics, Inc. (NYSE:PLX - Free Report) - Investment analysts at Zacks Small Cap decreased their FY2024 earnings per share estimates for shares of Protalix BioTherapeutics in a research note issued to investors on Thursday, August 22nd. Zacks Small Cap analyst J. Vandermosten nowAugust 26, 2024 | marketbeat.comPLX: A Focus on Renal Rare DiseaseAugust 22, 2024 | finance.yahoo.comPLX Sep 2024 7.500 call (PLX240920C00007500)August 17, 2024 | finance.yahoo.comProtalix BioTherapeutics (NYSE:PLX) Releases Earnings Results, Misses Expectations By $0.05 EPSProtalix BioTherapeutics (NYSE:PLX - Get Free Report) released its quarterly earnings results on Wednesday. The company reported ($0.03) earnings per share for the quarter, missing analysts' consensus estimates of $0.02 by ($0.05). The company had revenue of $13.47 million for the quarter, compared to analyst estimates of $12.50 million. Protalix BioTherapeutics had a return on equity of 19.48% and a net margin of 11.48%. During the same period in the previous year, the business posted ($0.07) EPS.August 15, 2024 | marketbeat.comProtalix BioTherapeutics, Inc.: Protalix BioTherapeutics Reports Second Quarter 2024 Financial and Business ResultsAugust 14, 2024 | finanznachrichten.deProtalix BioTherapeutics, Inc. (PLX) Q2 2024 Earnings Call TranscriptAugust 14, 2024 | seekingalpha.comProtalix BioTherapeutics Reports Second Quarter 2024 Financial and Business ResultsAugust 14, 2024 | prnewswire.comWhat Wall Street expects from Protalix BioTherapeutics's earningsAugust 13, 2024 | markets.businessinsider.comPLX Aug 2024 0.500 put (PLX240816P00000500)July 28, 2024 | finance.yahoo.comProtalix BioTherapeutics (NYSE:PLX) Trading Down 7.1%Protalix BioTherapeutics (NYSE:PLX) Stock Price Down 7.1%July 5, 2024 | marketbeat.comProtalix BioTherapeutics to Host In-Person Investor Day to Discuss Current Treatment Landscapes and Clinical Results for Fabry Disease and Uncontrolled GoutJune 13, 2024 | prnewswire.comProtalix BioTherapeutics (NYSE:PLX) Trading 0.4% Higher Protalix BioTherapeutics (NYSE:PLX) Trading Up 0.4%June 13, 2024 | marketbeat.comProtalix BioTherapeutics to Present at the 2024 BIO International ConventionMay 29, 2024 | prnewswire.comPLX: First Quarter UpdateMay 15, 2024 | finance.yahoo.comProtalix BioTherapeutics Inc (PLX) Q1 2024 Earnings Call Transcript Highlights: Navigating ...May 13, 2024 | finance.yahoo.comEarnings call: Protalix BioTherapeutics Q1 2024 financial resultsMay 12, 2024 | investing.comProtalix BioTherapeutics, Inc. (AMEX:PLX) Q1 2024 Earnings Call TranscriptMay 11, 2024 | finance.yahoo.comPLX Stock Earnings: Protalix BioTherapeutics Misses EPS, Misses Revenue for Q1 2024May 10, 2024 | investorplace.comNovavax, Macrogenics, Biofrontera among healthcare moversMay 10, 2024 | msn.comStocks See Support from Higher Chip Stocks and Earnings OptimismMay 10, 2024 | msn.comProtalix BioTherapeutics Inc. Q1 Loss Increases, Misses EstimatesMay 10, 2024 | markets.businessinsider.comProtalix BioTherapeutics Reports First Quarter 2024 Financial and Business ResultsMay 10, 2024 | prnewswire.comProtalix BioTherapeutics earnings: here's what Wall Street expectsMay 9, 2024 | markets.businessinsider.comProtalix BioTherapeutics to Announce First Quarter 2024 Financial and Business Results on May 10, 2024May 3, 2024 | finance.yahoo.comProtalix BioTherapeutics, Inc. (PLX) Q4 2023 Earnings Call TranscriptMarch 16, 2024 | seekingalpha.comEarnings call: Protalix BioTherapeutics reports fiscal year 2023 resultsMarch 16, 2024 | uk.investing.comProtalix BioTherapeutics (NYSE:PLX) Downgraded to "Hold" at StockNews.comStockNews.com cut Protalix BioTherapeutics from a "buy" rating to a "hold" rating in a research note on Friday.March 15, 2024 | marketbeat.comProduction cuts, geopolitical tensions drive oil rallyMarch 15, 2024 | ca.finance.yahoo.comProtalix BioTherapeutics, Inc. (AMEX:PLX) Q4 2023 Earnings Call TranscriptMarch 15, 2024 | finance.yahoo.comPLX: Elfabrio Geographic ExpansionMarch 15, 2024 | finance.yahoo.comProtalix BioTherapeutics, Inc.: Protalix BioTherapeutics Reports Fiscal Year 2023 Financial and Business ResultsMarch 14, 2024 | finanznachrichten.deProtalix BioTherapeutics Inc Reports Revenue Growth and Net Income Gain in FY 2023March 14, 2024 | finance.yahoo.comProtalix BioTherapeutics Reports Fiscal Year 2023 Financial and Business ResultsMarch 14, 2024 | prnewswire.comHere's what Wall Street expects from Protalix BioTherapeutics's earnings reportMarch 13, 2024 | markets.businessinsider.comEarnings Preview: Protalix BioTherapeuticsMarch 13, 2024 | benzinga.com Get Protalix BioTherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PLX and its competitors with MarketBeat's FREE daily newsletter. Email Address Could This Tiny Device Help You Make an Extra $30k a Year? (Ad)I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more than $9 trillion. That’s nearly 10 times more money than the market caps of Tesla… SpaceX… PayPal… Neuralink… and X… COMBINED. Click here to see the details because I believe a lot of people will get rich. PLX Media Mentions By Week PLX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PLX News Sentiment▼0.000.60▲Average Medical News Sentiment PLX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PLX Articles This Week▼11▲PLX Articles Average Week Get Protalix BioTherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PLX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies AnaptysBio News CorMedix News Mereo BioPharma Group News Xeris Biopharma News ABIVAX Société Anonyme News MeiraGTx News Cartesian Therapeutics News Monte Rosa Therapeutics News Alpha Teknova News Organogenesis News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:PLX) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Protalix BioTherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Protalix BioTherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PLX Stock Alerts